Abstract: Neuraminidase (NA), a glycoprotein on the surface of the influenza virus, plays a crucial role in viral escape and serves as a stable target for drug candidates. Monoclonal antibodies targeting the NA active site can bind to multiple influenza virus subtypes and inhibit the spread of influenza virus through various mechanisms, such as neutralizing, mediating antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. In vivo experiments have shown that human monoclonal antibodies targeting the influenza virus NA can effectively exert preventive and therapeutic effects, rescuing mice infected with lethal doses and reducing viral titers in lungs of mice. This article provides a review of the currently reported human monoclonal antibodies targeting NA of Influenza A and Influenza B viruses, providing new ideas and prospects for the subsequent development of anti-influenza drugs.